Skip to main content
Erschienen in: Rheumatology International 5/2017

20.03.2017 | Epidemiology of RMD

Anti-Toxoplasma antibodies in Egyptian rheumatoid arthritis patients

verfasst von: Abeer A. El-Henawy, Eman Abdel Razek Hafez, Nairmen Nabih, Naglaa M. Shalaby, Mervat Mashaly

Erschienen in: Rheumatology International | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess seroprevalence of anti-Toxoplasma gondii antibodies; both IgG and IgM in Egyptian rheumatoid arthritis (RA) patients versus a non-RA group and to compare anti-Toxoplasma antibodies seroprevalence among RA patients receiving traditional treatment and RA patients treated with biologic drug.

Methods

60 RA patients and 60 healthy controls were enrolled in the study. Patients were categorized into two groups: one group included 30 patients receiving disease modifying anti-rheumatic drugs (DMARDs), while the other group included 30 patients receiving biologic agent, infliximab, a TNF-α antagonist. Serum samples of all investigated persons were examined for anti-Toxoplasma antibodies. RA activity markers including rheumatoid factor, anti-cyclic citrullinated protein antibodies, C reactive protein, ESR in addition to disease activity score 28 (DAS28) of RA patients were also evaluated to explore their association with Toxoplasma seropositivity.

Results

Anti-Toxoplasma IgG antibodies were detected among 46/60 RA patients (76.7%) versus 29/60 controls (48.3%), (p = 0.001). Anti-Toxoplasma IgG titre was higher among RA group [median, (range) = 232.940 (8.949–653.242) IU/ml] than among controls [median, (range) = 68.820 (2.450–318.945) IU/ml], (p < 0.001). No difference was detected among RA patients either on traditional or biologic treatment regarding anti-Toxoplasma IgG antibodies. No positive anti-Toxoplasma IgM was detected. A positive correlation was detected between anti-Toxoplasma IgG titre and disease activity markers.

Conclusion

Higher seroprevalence of anti-Toxoplasma IgG antibodies among RA patients compared to controls reflects an association between latent Toxoplasma infection and RA. Our findings support previous studies and necessitate future large-scale studies to elucidate the exact role of Toxoplasma whether a trigger of autoimmunity in RA or an effect of immunosuppression.
Literatur
2.
Zurück zum Zitat Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205–1213CrossRefPubMed Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205–1213CrossRefPubMed
3.
Zurück zum Zitat McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219CrossRefPubMed McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219CrossRefPubMed
4.
Zurück zum Zitat Skariah S, McIntyre MK, Mordue DG (2010) Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion. Parasitol Res 107(2):253–260CrossRef Skariah S, McIntyre MK, Mordue DG (2010) Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion. Parasitol Res 107(2):253–260CrossRef
5.
Zurück zum Zitat Fromont EG, Riche B, Rabilloud M (2009) Toxoplasma seroprevalence in a rural population in France: detection of a household effect. BMC Infect Dis 9:76CrossRefPubMedPubMedCentral Fromont EG, Riche B, Rabilloud M (2009) Toxoplasma seroprevalence in a rural population in France: detection of a household effect. BMC Infect Dis 9:76CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168e77. Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168e77.
7.
Zurück zum Zitat Shapira Y, Agmon-Levin N, Selmi C, Petríková J, Barzilai O, Rama M et al (2012) Prevalence of anti-Toxoplasma antibodies in patients with autoimmune diseases. J Autoimmun 39(1–2):112–116CrossRefPubMed Shapira Y, Agmon-Levin N, Selmi C, Petríková J, Barzilai O, Rama M et al (2012) Prevalence of anti-Toxoplasma antibodies in patients with autoimmune diseases. J Autoimmun 39(1–2):112–116CrossRefPubMed
9.
Zurück zum Zitat El-Sayed NM, Kishik SM, Fawzy RM (2016) The current status of Toxoplasma gondii infection among Egyptian rheumatoid arthritis patients. Asian Pac J Trop Dis 6(10):797–801.CrossRef El-Sayed NM, Kishik SM, Fawzy RM (2016) The current status of Toxoplasma gondii infection among Egyptian rheumatoid arthritis patients. Asian Pac J Trop Dis 6(10):797–801.CrossRef
10.
Zurück zum Zitat Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639CrossRef Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639CrossRef
11.
Zurück zum Zitat Maini R, St Clair EW, Breedveld F, Frust D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. The Lancet 354(9194):1932–1939CrossRef Maini R, St Clair EW, Breedveld F, Frust D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. The Lancet 354(9194):1932–1939CrossRef
12.
Zurück zum Zitat Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6):478–486CrossRefPubMed Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6):478–486CrossRefPubMed
13.
Zurück zum Zitat Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45CrossRefPubMed Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45CrossRefPubMed
14.
Zurück zum Zitat St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443CrossRefPubMed St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443CrossRefPubMed
15.
Zurück zum Zitat Shim H (2011) One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med 43(10):539–549CrossRefPubMedPubMedCentral Shim H (2011) One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med 43(10):539–549CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRefPubMed Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRefPubMed
17.
Zurück zum Zitat Fransen J, Stucki G, van Riel PLCM (2003) Rheumatoid arthritis measures: disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Rheum 49(S5):S214–S224CrossRef Fransen J, Stucki G, van Riel PLCM (2003) Rheumatoid arthritis measures: disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Rheum 49(S5):S214–S224CrossRef
19.
Zurück zum Zitat Zaccone P, Oliver T, Burton OT, Cooke A (2007) Interplay of parasite-driven immune responses and autoimmunity. Trends Parasitol 24(1):35–42CrossRefPubMed Zaccone P, Oliver T, Burton OT, Cooke A (2007) Interplay of parasite-driven immune responses and autoimmunity. Trends Parasitol 24(1):35–42CrossRefPubMed
20.
Zurück zum Zitat OsadaY, Shimizu S, KumagaiT, Yamada S, Kanazawa T (2009) Schistosoma mansoni infection reduces severity of collagen-induced arthritis via down-regulation of pro-inflammatory mediators. Int J Parasitol 39:457–464CrossRef OsadaY, Shimizu S, KumagaiT, Yamada S, Kanazawa T (2009) Schistosoma mansoni infection reduces severity of collagen-induced arthritis via down-regulation of pro-inflammatory mediators. Int J Parasitol 39:457–464CrossRef
21.
Zurück zum Zitat Salinas-Carmona MC, de la Cruz-Galicia G, Pérez-Rivera I, Solís-Soto JM, Segoviano-Ramirez JC, Vázquez AV, Garza MA (2009) Spontaneous arthritis in MRL/lpr mice is aggravated by Staphylococcus aureus and ameliorated by Nippostrongylus brasiliensis infections. Autoimmunity 42(1):25–32CrossRefPubMed Salinas-Carmona MC, de la Cruz-Galicia G, Pérez-Rivera I, Solís-Soto JM, Segoviano-Ramirez JC, Vázquez AV, Garza MA (2009) Spontaneous arthritis in MRL/lpr mice is aggravated by Staphylococcus aureus and ameliorated by Nippostrongylus brasiliensis infections. Autoimmunity 42(1):25–32CrossRefPubMed
22.
Zurück zum Zitat Engman DM, Leon JS (2002) Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop 81:123–132CrossRefPubMed Engman DM, Leon JS (2002) Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop 81:123–132CrossRefPubMed
23.
Zurück zum Zitat Sert M, Ozbek S, Paydas S, Yaman A (2007) Is there any relationship between Toxoplasma infection and reactive arthritis? J Postgrad Med 53:14–16CrossRefPubMed Sert M, Ozbek S, Paydas S, Yaman A (2007) Is there any relationship between Toxoplasma infection and reactive arthritis? J Postgrad Med 53:14–16CrossRefPubMed
25.
Zurück zum Zitat Liesenfeld O, Kosek J, Remington JS, Suzuki Y (1996) Association of CD4 + T cell-dependent, IFN-g mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med 184:597–607CrossRefPubMed Liesenfeld O, Kosek J, Remington JS, Suzuki Y (1996) Association of CD4 + T cell-dependent, IFN-g mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med 184:597–607CrossRefPubMed
26.
Zurück zum Zitat Liesenfeld O (2002) Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 185:S96–S101CrossRefPubMed Liesenfeld O (2002) Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 185:S96–S101CrossRefPubMed
27.
Zurück zum Zitat Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Bizzaro N et al (2009) Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann NY Acad Sci 1173:640–648CrossRefPubMed Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Bizzaro N et al (2009) Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann NY Acad Sci 1173:640–648CrossRefPubMed
28.
Zurück zum Zitat Garweg JG, De Kozak Y, Goldenberg B, Graefes MB (2010) Anti-retinal autoantibodies in experimental ocular and systemic toxoplasmosis. Arch Clin Exp Ophthalmol 248:573–584CrossRef Garweg JG, De Kozak Y, Goldenberg B, Graefes MB (2010) Anti-retinal autoantibodies in experimental ocular and systemic toxoplasmosis. Arch Clin Exp Ophthalmol 248:573–584CrossRef
29.
Zurück zum Zitat Elsheikha HM, Azab MS, Abousamra NK, Rahbar MH, Elghannam DM, Raafat D (2009) Seroprevalence of and risk factors for Toxoplasma gondii antibodies among asymptomatic blood donors in Egypt. Parasitol Res 104:1471–1476CrossRefPubMed Elsheikha HM, Azab MS, Abousamra NK, Rahbar MH, Elghannam DM, Raafat D (2009) Seroprevalence of and risk factors for Toxoplasma gondii antibodies among asymptomatic blood donors in Egypt. Parasitol Res 104:1471–1476CrossRefPubMed
30.
Zurück zum Zitat Al-Kappany YM, Rajendran C, Ferreira LR, Kwok OCH, Abu-Elwafa SA, Hilali M, Dubey JP (2010) High prevalence of toxoplasmosis in cats from Egypt: isolation of viable Toxoplasma gondii, tissue distribution, and isolate designation. J Parasitol 96(6):1115–1118CrossRefPubMed Al-Kappany YM, Rajendran C, Ferreira LR, Kwok OCH, Abu-Elwafa SA, Hilali M, Dubey JP (2010) High prevalence of toxoplasmosis in cats from Egypt: isolation of viable Toxoplasma gondii, tissue distribution, and isolate designation. J Parasitol 96(6):1115–1118CrossRefPubMed
31.
Zurück zum Zitat Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV (2009) Leishmaniasis, autoimmune rheumatic aisease, and anti–tumor necrosis factor therapy, Europe. Emerg Infect Dis 15(6):956–959CrossRefPubMedPubMedCentral Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV (2009) Leishmaniasis, autoimmune rheumatic aisease, and anti–tumor necrosis factor therapy, Europe. Emerg Infect Dis 15(6):956–959CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Young JD, McGwire BS (2005) Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 353(14):1530–1531CrossRefPubMed Young JD, McGwire BS (2005) Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 353(14):1530–1531CrossRefPubMed
33.
Zurück zum Zitat Lassoued S, Zabraniecki L, Marin F, Billey T (2007) Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum 36(4):262–263CrossRefPubMed Lassoued S, Zabraniecki L, Marin F, Billey T (2007) Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum 36(4):262–263CrossRefPubMed
34.
Zurück zum Zitat Azevedo VF, Pietrovski CF, de Almeida Santos Jr M (2010) Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report. Reumatismo 62(4):283–285PubMed Azevedo VF, Pietrovski CF, de Almeida Santos Jr M (2010) Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report. Reumatismo 62(4):283–285PubMed
35.
Zurück zum Zitat Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S (2014) Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford) 53(2):284CrossRef Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S (2014) Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford) 53(2):284CrossRef
36.
Zurück zum Zitat 36-Cren JB, Bouvard B, Crochette N (2016) Cerebral toxoplasmosis and anti-TNF-α: a case report. ID Cases 5:40–42.PubMedPubMedCentral 36-Cren JB, Bouvard B, Crochette N (2016) Cerebral toxoplasmosis and anti-TNF-α: a case report. ID Cases 5:40–42.PubMedPubMedCentral
37.
Zurück zum Zitat van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW (1994) Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 53(4):224–228CrossRefPubMedPubMedCentral van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW (1994) Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 53(4):224–228CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Deeming GM, Collingwood J, Pemberton MN (2005) Methotrexate and oral ulceration. Br Dent J 198(2):83–85CrossRefPubMed Deeming GM, Collingwood J, Pemberton MN (2005) Methotrexate and oral ulceration. Br Dent J 198(2):83–85CrossRefPubMed
39.
Zurück zum Zitat Kuba RH, Zghair KH, Alosami MH (2014) Detection of Toxoplasma antibodies and TNF-α in rheumatoid arthritis patients treated with methotrexate. Iraqi J Sci 55:1535–1540 Kuba RH, Zghair KH, Alosami MH (2014) Detection of Toxoplasma antibodies and TNF-α in rheumatoid arthritis patients treated with methotrexate. Iraqi J Sci 55:1535–1540
40.
Zurück zum Zitat Wallis RS, Broder M, Wong J, Lee A, Hoq L (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41(supple 3):S194–S198CrossRefPubMed Wallis RS, Broder M, Wong J, Lee A, Hoq L (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41(supple 3):S194–S198CrossRefPubMed
41.
Zurück zum Zitat Toussirot É, Streit G, Wendling D, Minjoz J, Fleming B, Cedex FB et al (2007) Infectious complications with anti-TNF-α diseases. Recent Pat Inflamm Allergy Drug Discov 1:39–47CrossRefPubMed Toussirot É, Streit G, Wendling D, Minjoz J, Fleming B, Cedex FB et al (2007) Infectious complications with anti-TNF-α diseases. Recent Pat Inflamm Allergy Drug Discov 1:39–47CrossRefPubMed
42.
Zurück zum Zitat Ustun C, Kallab A, Loebl D, Jillela A, Majewski B, Mazzella F et al (2002) Rheumatoid arthritis and immune thrombocytopenia: a report of two cases. Clin Rheumatol 21:543–544CrossRefPubMed Ustun C, Kallab A, Loebl D, Jillela A, Majewski B, Mazzella F et al (2002) Rheumatoid arthritis and immune thrombocytopenia: a report of two cases. Clin Rheumatol 21:543–544CrossRefPubMed
43.
Zurück zum Zitat Toth P, Bernd R (2014) Severe leukopenia in a rheumatoid arthritis patient treated with a methotrexate/leflunomide combination. Rev Bras Reumatol 54(2):152–154CrossRefPubMed Toth P, Bernd R (2014) Severe leukopenia in a rheumatoid arthritis patient treated with a methotrexate/leflunomide combination. Rev Bras Reumatol 54(2):152–154CrossRefPubMed
Metadaten
Titel
Anti-Toxoplasma antibodies in Egyptian rheumatoid arthritis patients
verfasst von
Abeer A. El-Henawy
Eman Abdel Razek Hafez
Nairmen Nabih
Naglaa M. Shalaby
Mervat Mashaly
Publikationsdatum
20.03.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 5/2017
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3703-8

Weitere Artikel der Ausgabe 5/2017

Rheumatology International 5/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.